



Biotech Daily

Monday July 8, 2013

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH EVEN: ANTISENSE UP 27%, PHYLOGICA DOWN 10%**
- * **RESONANCE, NOVARTIS STUDY BACKS FERRISCAN MONITOR**
- * **ALLIED HEALTH CARDIOCEL SPECIAL ADULT APPROVAL**
- * **ISONEA RAISES \$13.5m; POKIES BRUCE MATHIESON TAKES 19%**
- * **BIONICHE COMPLETES \$8m PALLADIN FINANCE**
- * **DAVID PLUSH, TEXAS WOODS 14% OF IMMURON; DIRECTOR RELATED**
- * **GENERA REQUESTS CAPITAL RAISING TRADING HALT**

MARKET REPORT

The Australian stock market fell 0.67 percent on Monday July 8, 2013 with the S&P ASX 200 down 32.2 points to 4,809.5 points.

Twelve of the Biotech Daily Top 40 stocks were up, 11 fell, 12 traded unchanged and five were untraded.

Antisense was the best, up 0.3 cents or 27.3 percent to 1.4 cents, with 48.1 million shares traded, followed by Prima up 11.5 percent to 9.7 cents with 11.4 million shares traded.

Clinuvel climbed 9.9 percent; Circadian was up 8.3 percent; Cellmid and Ellex were up more than seven percent; both QRX and Tissue Therapies were up four percent; Allied Health and Universal Biosensors were up more than three percent; Living Cell and Osprey were up more than one percent; with Resmed up 0.6 percent.

Phylogica led the falls, down 0.2 cents or 9.5 percent to 1.9 cents with 66,000 shares traded.

Patrys lost 7.4 percent; Neuren fell 6.4 percent; Alchemia, Anteo and Starpharma were down more than three percent; Medical Developments and Nanosonics shed more than two percent; Mesoblast and Sirtex were down more than one percent; with Cochlear, CSL and Psivida down by less than one percent.

RESONANCE HEALTH

Resonance says a study of its Ferriscan R2-MRI has confirmed its clinical utility for monitoring iron overload.

Resonance said the study, co-authored by director Prof Timothy St Pierre, entitled 'Multicenter validation of spin-density projection-assisted R2-MRI for the non-invasive measurement of liver iron concentration' was published in the Magnetic Resonance in Medicine and was at: <http://onlinelibrary.wiley.com/doi/10.1002/mrm.24854/full>.

Resonance said the study was conducted on a group of 233 thalassaemia patients ranging from three years of age at five clinical centres.

The study, sponsored by Novartis Pharma AG, concluded that "The calibration curve appears independent of scanner type, patient age, stage of liver fibrosis, grade of necro-inflammation, and use of deferasirox chelation therapy, confirming the clinical usefulness of SDPA R2-MRI for monitoring iron overload".

The company said its Ferriscan R2-MRI was "the gold standard for non-invasive MRI measurement of liver iron concentration ... [which was] further substantiated by the publication of a paper demonstrating that the technology can be used in different MRI centres on different makes and models of scanners with no impact on the accuracy of the liver iron concentration result".

Resonance said that the Ferriscan R2-MRI had clearance from the US Food and Drug Administration, Australian Therapeutic Goods Administration and other regulatory authorities and carried the Conformité Européenne (CE) mark in Europe.

Resonance said that the Ferriscan was used in hospitals for measurement of liver iron concentration in patients who are at risk of liver iron overload, incurred through chronic blood transfusions required in the treatment of diseases such as thalassaemia, sickle cell disease and myelodysplastic syndrome.

The company said that iron chelation therapy required safe, accurate measurement of iron overload and the R2-MRI had been included in many guidelines and protocols.

Resonance was untraded at 1.1 cents.

ALLIED HEALTHCARE GROUP

Allied Health says that Brisbane cardiac surgeon Dr Homayoun Jalali has been granted special approval to use Cardiocel to treat and repair heart defects.

Allied said that Dr Jalali was the sixth surgeon to obtain access to use the Cardiocel Adapt-treated bovine cardiac tissue under the Authorised Prescriber Scheme early access schemes allowing use prior to full marketing approval.

Allied chief executive officer Lee Rodne said the adult approval was "a key step" allowing the first use of Cardiocel in adults and had "the potential to increase market potential and revenue for the company considerably".

"Cardiocel offers considerable ease of use for surgeons, as it can be used straight out of the box, and we are encouraged to see growing support for the product both locally and internationally," Mr Rodne said.

Allied said that Cardiocel was used to repair heart deformities including repairing and reconstructing heart valves and 10 years of studies had shown no evidence of cytotoxicity or calcification at the site of repair for four years post-surgery.

The company said that Cardiocel had shown superior stem cell survival and regenerative properties when compared with existing gold standard patches.

Allied said it had filed for marketing approval for Cardiocel with both the European Regulatory Authority and the US Food and Drug Administration.

Allied was up 0.2 cents or 3.85 percent to 5.4 cents with 9.5 million shares traded.

ISONEA

Isona says it has raised \$13,500,000 through a placement at 35 cents a share for its Airsona smart phone-based asthma monitor.

Investment Holdings, an entity owned by gambling machine operator Bruce Mathieson said it increased its holding in Isona from 17,500,000 shares (13.01%) to 48,000,000 shares (18.59%), acquiring 10,500,000 shares for \$525,000 in a rights issue at five cents a share in 2012 and a further 20,000,000 shares in the placement (BD: Oct 30, 2012). Isona was unchanged at 49 cents.

BIONICHE LIFE SCIENCES

Bioniche says it has completed its financing arrangement with Paladin Labs to refinance and increase debt, provide new equity and enter into the first licence for Urocidin.

Last month, Bioniche said that Paladin agreed to provide a \$C8 million (\$A8.35 million) loan to support ongoing operations, \$C5 million of which would be available on closing of the transaction and \$C3 million which would be available on Bioniche's receipt of equity in the form of licencing revenue or an equity financing (BD: Jun 6, 2013).

Today, Bioniche said Paladin had issued a further \$C5 million in debt financing and as partial consideration it granted Paladin warrants over shares, expiring on the earlier of two years from the complete repayment by Bioniche of the loan or May 31, 2019.

The company said it has issued 2,000,000 at exercise prices from 31 Canadian cents to \$C1.00 and if the loan was not repaid by January 1, 2014, 500,000 warrants would be exercisable at the 5-day volume weighted average share price at December 31, 2013 and if not repaid by April 1, 2014, 500,000 warrants would be exercisable at the 5-day volume weighted average share price at March 31, 2014.

Bioniche said it did not need shareholder approval for the issue of the warrants. Bioniche was untraded at 30 cents.

IMMURON

David Plush and Texas Woods Pty Ltd have become substantial shareholders in Immuron with the acquisition of 146,576,329 shares or 14.42 percent of the company.

The Melbourne-based entities said in the substantial shareholder notice that Mr Plush was a director of Texas Woods, which held more than 20 percent of Grandlodge Pty Ltd.

In May, Grandlodge Pty Ltd and the Anastasiou Superannuation Fund became 16.56 percent substantial in Immuron and the company appointed Stephen Anastasiou as a non-executive director (BD: May 7, 28, 2013).

Today, Mr Plush said the shares were bought between May 3 and June 28, 2013 at prices from 0.3 cents to 0.4 cents a share.

Immuron was unchanged at 0.7 cents with two million shares traded.

GENERA BIOSYSTEMS

Genera has requested a trading halt pending an announcement "in relation to a capital raising".

Trading will resume on July 10, 2013 or on an earlier announcement.

Genera last traded at 10.5 cents.